RecruitingOverweightPrediabetic StatePrehypertension

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Eligible age

18+ yrs

Accepts

All genders

Locations

31 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have an increased waist-to-height ratio of ≥0.5
✓ Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
✓ Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
✓ Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds

You may not qualify if…

✕ Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
✕ Do not have a stable body weight within 90 days before screening
✕ Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
✕ Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
✕ Have a prior or planned surgical treatment or procedure for obesity
✕ Have hypertension or history of hypertension
✕ Have dyslipidemia or history of dyslipidemia